Cariprazine as a therapeutic option for schizophrenia: a drug evaluation. (4th March 2021)

• Record Type: Journal Article
• Authors: Mucci, Federico; Della Vecchia, Alessandra; Baroni, Stefano; Marazziti, Donatella
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 4(2021)
• Page Start: 415
• Page End: 426
• Publication Date: 2021-03-04
• Subjects: Schizophrenia -- psychosis -- negative symptoms -- antipsychotics -- second-generation antipsychotics -- cariprazine -- partial agonism -- dopamine receptors; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2020.1845315
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Schizophrenia is a very disabling condition that may result in a significant impairment of individual, professional, and social adjustments. Antipsychotics (APs), the first-line treatment for schizophrenia, in many cases modify the course of the disease, by reducing the institutionalization risk, at the price of severe and invalidating side effects. Cariprazine is one of the latest second-generation APs (SGAs) acting as a partial agonist of type 2 and 3 dopamine receptors, which was recently approved for the treatment of adult schizophrenia. Areas covered : The authors provide a critical review and commentary on the currently available data on the effectiveness and tolerability of cariprazine in schizophrenic patients, with a particular focus on its specific target symptoms. Expert opinion : Cariprazine appears significantly effective on both acute and maintenance treatment of schizophrenia, and in improving positive, negative, and cognitive symptoms, slightly more than other SGAs. It shows a good safety and tolerability profile, with akathisia being its most common side effect. Although further independent studies are needed to clarify its precise advantages over other SGAs, cariprazine seems a promising compound not only in schizophrenia, but also in a broad range of psychiatric conditions, including perhaps bipolar and addictive disorders.